FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

KI I	112	AND	EXC	TANGE	COMIN	122101

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average hurden										

hours per response:

0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Novo Holdings A/S					2. Issuer Name and Ticker or Trading Symbol Galera Therapeutics, Inc. [ GRTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X 10% Owne					
(Last) (First) (Middle) TUBORG HAVNEVEJ 19					3. Date of Earliest Transaction (Month/Day/Year) 11/12/2019								Officer (give title X Other (specify below)  SEE REMARKS					
(Street) HELLERUP G7 2900  (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
. , , ,	`		able I - Noi	n-Deriva	tive S	ecu	rities Acc	uired.	Disi	osed o	f. or	Benef	icially Ov	vned				
1. Title of Security (Instr. 3)  2. Tr. Date				2. Transact			3. 4. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			A) or	5. Amount Securities Beneficially Following F		6. Own Form: (D) or I (I) (Inst	Direct ndirect tr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v			Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
COMMON STOCK 11.				11/12/2	2/2019		С		2,373,152		A	(1)	2,373,152			D		
COMMON STOCK 11/					2/2019		С		535,869		A	(1)	2,909,021		D			
COMMON STOCK 11				11/12/2	2/2019			P		500,000		A	\$12 <sup>(2)</sup>	3,409,021		D		
							ties Acqu warrants,							ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	, Transaction Code (Instr.		Derivative		6. Date Exercisa Expiration Date (Month/Day/Yea		Securities Underl		derlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisa		Expiration Date	Title	- 1	Amount or Number of Shares		(Instr. 4)			
SERIES B PREFERRED	(1)	11/12/2019		С			12,000,000	(1)		(1)	COM		2,373,152	\$0.00	0		D	

## **Explanation of Responses:**

1. Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, in accordance with the applicable conversion ratio, resulting in the acquisition of the number of shares of Common Stock shown. There was no expiration date for the preferred stock.

2,709,659

11/12/2019

## Remarks:

SERIES C

PREFERRED

Novo Holdings A/S is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board") has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.

(1)

/s/ Peter Haahr, Chief Financial 11/14/2019 Officer of Novo Holdings A/S

535,869

\$0.00

0

COMMON

STOCK

(1)

\*\* Signature of Reporting Person

Date

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

C

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> Represents a purchase from the underwriters in the Issuer's public offering.